• All
  • --
  • ---
  • -2022
  • 2022-2
  • 2022-2-2-2
  • 2022-deltia-tipoy
  • 2022-deltia-tipoy-2-2
  • 2022-deltia-tipoy-2-2-2-2
  • 2023-deltia-typou
  • 2023-deltia-typou-2-2
  • 2024
  • 257-2
  • 257-2-2-2
  • 266-2
  • Announcements
  • Announcements 2025
  • Consolidated Financial Results
  • deltia-tipoy
  • deltia-tipoy-2-2
  • deltia-tipoy-2-2-2-2
  • Distribution of Divident
  • Events
  • FAQ
  • General Meetings and Corporate Actions
  • Insiders Transactions Disclosures
  • Invitations
  • invitations-2
  • Presentations
  • Press Kits
  • Press Releases
  • Regulated Information
  • Results 2024
  • Share Capital Increase
  • Uncategorized

  2010 was undoubtedly one of the most demanding years, with great challenges facing every segment of the national economy. The turmoil created in the Greek pharmaceutical market since the beginning of the year has seriously affected the turnover of pharmaceutical companies. The price changes, which...

  Modern, fresh, rich in information is the new website www.castalia-derm.com of CASTALIA LABORATOIRES DERMATOLOGIQUES. Through its pages, CASTALIA informs visitors about its philosophy and presents its dermocosmetic lines in an easy and user friendly way. Colors play an important role in www.castalia-derm.com, since each color used...

  In a difficult financial environment, with constant changes in the legal framework of the health sector, and especially in pharmaceuticals, Lavipharm has further strengthened its extrovert activities, aiming to an even greater growth of exports. At the same time, the company implemented its long-term plan...

  On Saturday, March 27th, all lights and electrical appliances at Lavipharm's headquarters in Peania and at its subsidiaries in Patra, Kavala, Gianenna and Larissa will be turned off for one hour. Lavipharm, participating for the second time in the "Earth Hour", takes this symbolic action...

  Consolidated Turnover posted an increase of 5%, reaching Euro 249.8 million compared to Euro 238.0 million during 2008. International Sales have increased by 17%, accounting for 11% of Total Sales. Gross Profit reached Euro 39.5 million from Euro 37.4 million in the last period (+5.6%)....

Lavipharm close to next generation Lavipharm supported once again the Association of Youth Entrepreneurship which the last 8 years cooperates with the country's schools as an educational tool to today's students and future professionals. Through the course of Career Forum, Lavipharm's executives played for a while...

  In anticipation of the decrease in drug prices, as expected since the beginning of the year, sales have dropped drastically, due to warehouses’ and pharmacies' effort to reduce inventories. As a consequence, Lavipharm's Consolidated Turnover fell to Euro 54.1 million from Euro 59.7 million in Q1...